Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Amends License Agreement with University of Utah, Yale

NEW YORK, April 29 (GenomeWeb News) - Genaissance Pharmaceuticals announced today that it has signed an amendment to its license agreement with the University of Utah and Yale University relating to cardiac ion channel genes associated with sudden cardiac death syndromes.


The amendment will simplify royalty payments for various genetic tests, including those for cardiac ion channel mutations, the company said. In addition, it will extend Genaissance's licensing rights to the patent estate.


Genaissance originally acquired the license agreement in May 2003 with the acquisition of most of the assets of DNA Sciences, whose IP portfolio included patents developed at Utah and Yale for diagnosing Long QT, Brugada and related syndromes associated with the cardiac ion channel genes.


The company said it expects to launch its test for cardiac ion channel mutations in May.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.